Abstract
The mevalonate pathway is important for the generation of isoprene moieties, thereby providing the basis for the biosynthesis of molecules required for maintaining membrane integrity, steroid production and cell respiration. Additionally, isoprene precursors are indispensable for the prenylation of regulatory proteins such as Ras and Ras-homologous (Rho) GTPases. These low molecular weight GTP-binding proteins play key roles in numerous signal transduction pathways stimulated upon activation of cell surface receptors by ligand binding. Thus, Ras/Rho proteins eventually regulate cell proliferation, tumor progression and cell death induced by anticancer therapeutics. Lipid modification of Ras/Rho proteins at their C-terminal CAAX-box is essential for their correct intracellular localization and function. Therefore, pharmacological inhibition of the isoprene metabolism is anticipated to impact the manifold biological functions attributed to Ras/Rho proteins. Here, the pros and cons of compounds that interfere with the mevalonate pathway for cancer treatment are summarized and discussed.
Keywords: Mevalonate pathway, protein prenylation, GTP-binding proteins, metastasis, anticancer drug resistance
Current Cancer Drug Targets
Title: Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Volume: 9 Issue: 5
Author(s): G. Fritz
Affiliation:
Keywords: Mevalonate pathway, protein prenylation, GTP-binding proteins, metastasis, anticancer drug resistance
Abstract: The mevalonate pathway is important for the generation of isoprene moieties, thereby providing the basis for the biosynthesis of molecules required for maintaining membrane integrity, steroid production and cell respiration. Additionally, isoprene precursors are indispensable for the prenylation of regulatory proteins such as Ras and Ras-homologous (Rho) GTPases. These low molecular weight GTP-binding proteins play key roles in numerous signal transduction pathways stimulated upon activation of cell surface receptors by ligand binding. Thus, Ras/Rho proteins eventually regulate cell proliferation, tumor progression and cell death induced by anticancer therapeutics. Lipid modification of Ras/Rho proteins at their C-terminal CAAX-box is essential for their correct intracellular localization and function. Therefore, pharmacological inhibition of the isoprene metabolism is anticipated to impact the manifold biological functions attributed to Ras/Rho proteins. Here, the pros and cons of compounds that interfere with the mevalonate pathway for cancer treatment are summarized and discussed.
Export Options
About this article
Cite this article as:
Fritz G., Targeting the Mevalonate Pathway for Improved Anticancer Therapy, Current Cancer Drug Targets 2009; 9 (5) . https://dx.doi.org/10.2174/156800909789057033
DOI https://dx.doi.org/10.2174/156800909789057033 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Poly(ethylene glycol)-polypeptide Copolymer Micelles for Therapeutic Agent Delivery
Current Pharmaceutical Biotechnology Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Modulation of Poly(A)-specific Ribonuclease (PARN): Current Knowledge and Perspectives
Current Medicinal Chemistry Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1
Current Pharmaceutical Design Multifunctional Mesoporous Silica Nanoparticles for Combined Therapeutic, Diagnostic and Targeted Action in Cancer Treatment
Current Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Ganglioside GD3 as a Raft Component in Cell Death Regulation
Anti-Cancer Agents in Medicinal Chemistry Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
Current Genomics HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins
Current Nanoscience The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Meet Our Co-Editor
Current Signal Transduction Therapy Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy